Dave Dixon explains impact of generic rivaroxaban-

The U.S. Food and Drug Administration (FDA) has approved the first generic versions of rivaroxaban, marking a significant milestone in the availability of direct-acting oral anticoagulants (DOACs). While this approval could expand access to newer anticoagulation therapies, experts caution that the immediate impact may be limited.

The newly approved generics are a 2.5 mg dose of rivaroxaban, which is indicated for reducing the risk of major cardiovascular events in adults with coronary artery disease and peripheral artery disease (PAD). However, this dose is not intended to be used for the treatment and prevention of venous thromboembolism (VTE), where DOACs like rivaroxaban have largely replaced warfarin.

Potential impact of generic DOACs on cardiology

Dave Dixon, PharmD, chair of the department of pharmacotherapy and outcomes science at Virginia Commonwealth University School of Pharmacy, emphasized the importance of this approval, but noted its limited scope.

“I think the big thing is that the FDA approved the first generic for the 2.5 mg dose of rivaroxaban, which is used for secondary prevention,” Dixon explained. “This is not the dose used for the treatment and prevention of VTE, so its impact is relatively modest for now.”